Recombinant Human EphA7 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6756-A7

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
6756-A7-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

NP_004431

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all EphA7 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human EphA7 protein
Human EphA7
(Met1 - Val555)
Accession # NP_004431		 IEGRMD Human IgG1
(Pro100 - Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala30 & Gln28, predicted, not obtained, sequencing might be blocked

Predicted Molecular Mass

85.7 kDa

SDS-PAGE

95-105 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.

When Recombinant Human (rh) EphA7 Fc Chimera is coated at 2 μg/mL (100 μL/well), the concentration of biotinylayed rhEphrin-A4 Fc Chimera that produces 50% of the optimal binding response is found to be approximately 1.5 ‑ 6 ng/mL.

Formulation, Preparation and Storage

6756-A7
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: EphA7

EphA7, also known as Mdk1, Hek11, Ehk3, Ebk, and Cek11, is a 115 ‑ 120 kDa glycosylated member of the Eph family of transmembrane receptor tyrosine kinases (1, 2). The A and B classes of Eph proteins are distinguished by Ephrin ligand binding preference but have a common structural organization. EphA7 preferentially binds to and is activated by Ephrin‑A1, ‑A2, ‑A3, ‑A4, and ‑A5 (3 ‑ 6). Eph‑Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression. The 532 amino acid (aa) extracellular domain (ECD) of human EphA7 contains an N‑terminal Ephrin binding region, a cysteine‑rich region, and two fibronectin type III domains (FnIII). The 421 aa cytoplasmic domain contains the tyrosine kinase domain and a sterile alpha motif (SAM) (7). Within the ECD, human EphA7 shares 98% aa sequence identity with mouse and rat EphA7. Alternate splicing generates secreted isoforms of human EphA7 that are truncated either before or following the first FnIII domain (7, 8). In mouse, EphA7 is expressed in discrete regions of the developing and adult neocortex (4, 9 ‑ 12), Purkinje layer of the cerebellum (10), limbic system (4, 9, 11, 12), visual and auditory systems (10, 11, 13), and the peripheral sensory nervous system (10, 11). EphA7 functions as a repulsive guidance molecule during the targeting of retinal axons to the superior colliculus  and of neocortical axons to the thalamus (4, 9, 13). EphA7 is also expressed in mesenchymal cells along routes of axon innervation during limb development (14). EphA7 ligands are expressed in a complementary pattern during embryogenesis (3, 9, 13, 14). EphA7 is selectively expressed in early stages of the B cell lineage, and a 50 kDa secreted form is produced by mature peripheral B and T cells (6, 15). This isoform is also expressed in human lung carcinoma (8). EphA7 can be up or down‑regulated in a variety of human cancers (6, 16, 17).

References

  1. Pasquale, E.B. (2005) Nat. Rev. Mol. Cell Biol. 6:462.
  2. Merlos-Suarez, A. and E. Batlle (2008) Curr. Opin. Cell Biol. 20:194.
  3. Ciossek, T. and A. Ullrich (1997) Oncogene 14:35.
  4. Miller, K. et al. (2006) J. Comp. Neurol. 496:627.
  5. Gale, N.W. et al. (1996) Neuron 17:9.
  6. Dawson, D.W. et al. (2007) Oncogene 26:4243.
  7. Fox, G.M. et al. (1995) Oncogene 10:897.
  8. Tsuboi, M. et al. (2010) Int. J. Oncol. 36:635.
  9. Torii, M. and P. Levitt (2005) Neuron 48:563.
  10. Ciossek, T. et al. (1995) Oncogene 9:97.
  11. Mori, T. et al. (1995) Mol. Brain Res. 34:154.
  12. Ciossek, T. et al. (1999) Mol. Brain Res. 74:231.
  13. Rashid, T. et al. (2005) Neuron 47:57.
  14. Araujo, M. et al. (1998) Development 125:4195.
  15. Aasheim, H.-C. et al. (1997) Blood 90:3613.
  16. Hafner, C. et al. (2004) Clin. Chem. 3:490.
  17. Wang, J. et al. (2007) Hum. Pathol. 38:1649.

Long Name

Eph Receptor A7

Alternate Names

Cek11, Ebk, Ehk3, Hek11, Mdk1

Entrez Gene IDs

2045 (Human); 13841 (Mouse)

Gene Symbol

EPHA7

UniProt

NP_004431

Additional EphA7 Products

Product Documents for Recombinant Human EphA7 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human EphA7 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.